

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/671,967
				Filing Date	September 25, 2003; Conf. No. 7271
				First Named Inventor	Jeffrey O. Saunders
				Art Unit	1621
				Examiner Name	Shailendra Kumar
Sheet	<b>1</b>	of	<b>5</b>	Attorney Docket Number	003601-0005-102

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> ( <i># known</i> )			
		US-3,973,038	08-03-1976	Umezawa et al.	
		US-4,028,394	06-07-1977	Karsten et al.	
		US-5,070,096	12-03-1991	Mohrs et al.	
		US-5,093,340	03-03-1992	Mohrs et al.	
		US-5,446,010	08-29-1995	Toyofuku et al.	
		US-5,721,246	02-24-1998	Yoshino et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i># known</i> )				
		CA 1041502	10-31-1978	Dr. Karl Thomae GmbH		
		CA 1206964	07-02-1986	Hoffmann La Roche Limited Canada		
		EP 0211568 B1	10-11-1989	Eli Lilly & Co.		
		EP 0221346 B1	01-13-1991	Warner Lambert Co.		
		EP 0279633 B1	04-07-1993	Eli Lilly & Co.		
		EP 0610653 B1	04-16-1997	New Oji Paper Co., Ltd.		
		EP 0673937 B1	11-26-2003	Eisai Co. Ltd.		
		GB 1459142	12-22-1976	Upjohn Co.		
		<b>GROUP A</b>				
		JP 08-512041 (English Language Abstract Attached)	12-17-1996	BYK Gulden Lomberg Chemische Fabrik GmbH		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/671,967
				Filing Date	September 25, 2003; Conf. No. 7271
				First Named Inventor	Jeffrey O. Saunders
				Art Unit	1621
				Examiner Name	Shailendra Kumar
Sheet	<b>2</b>	of	<b>5</b>	Attorney Docket Number	003601-0005-102

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
		JP 09-157236 (English Language Abstract Attached)	06-17-1997	Shiseido Co. Ltd.		
		<b><u>GROUP B</u></b>				
		JP 06-297860 (English Language Abstract Attached; English Language Counterpart Submitted as US 5,446,010)	10-25-1994	New Oji Paper Co. Ltd.		
		JP 07-165708 (English Language Abstract Attached; English Language Counterpart Submitted as US 5,721,246)	06-27-1995	Eisai Co. Ltd.		
		JP 63-093765 (English Language Abstract Attached; English Language Counterpart Submitted as US 5,093,340)	04-25-1988	Bayer AG		
		<b><u>GROUP C</u></b>				
		EP 0051819 (English Language Counterpart Submitted as CA 1206964)	02-13-1985	Hoffmann La Roche & Co.		
		JP 49-102693 (English Language Counterpart Submitted as CA 1041502)	09-27-1974	Dr. Karl Thomae GmbH		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/671,967
				Filing Date	September 25, 2003; Conf. No. 7271
				First Named Inventor	Jeffrey O. Saunders
				Art Unit	1621
				Examiner Name	Shailendra Kumar
Sheet	<b>3</b>	of	<b>5</b>	Attorney Docket Number	003601-0005-102

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)				
		JP 49-127939 (English Language Counterpart Submitted as GB 1459142)	12-07-1974	Upjohn Co.		
		JP 62-029562 (English Language Counterpart Submitted as EP 0211568)	02-07-1987	Eli Lilly & Co.		
		JP 62-081359 (English Language Counterpart Submitted as EP 0221346)	04-14-1987	Warner Lambert Co.		
		JP 63-222152 (English Language Counterpart Submitted as EP 0279633)	09-16-1988	Eli Lilly & Co.		
		JP 06-199047 (English Language Counterpart Submitted as EP 0610653)	07-19-1994	New Oji Paper Co. Ltd.		
		<b><u>GROUP D</u></b>				
		CH 332480 (English Language Claims Attached)	09-15-1958	J.R. Geigy AG, Basel		
		JP 08-143525 (English Language Abstract Attached)	06-04-1996	Banyu Pharma Co. Ltd.		
		JP 57-122039 (English Language Abstract Attached)	07-29-1982	Hoffmann La Roche & WAGF		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/671,967	
			Filing Date	September 25, 2003; Conf. No. 7271	
			First Named Inventor	Jeffrey O. Saunders	
			Art Unit	1621	
			Examiner Name	Shailendra Kumar	
Sheet	<b>4</b>	of	<b>5</b>	Attorney Docket Number	003601-0005-102

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
		ALLAY et al., "Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors," <i>Blood</i> , 90(9):3546-3554 (1997)		
		CECHINEL-FILHO et al., "Synthesis of xanthoxylone derivatives with antinociceptive and antioedematogenic activities," <i>European Journal of Medicinal Chemistry</i> , 31(10):833-839 (1996)		
		CHEN et al., "Structure-activity relationships in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interactions," <i>Journal of Medicinal Chemistry</i> , 37(6):845-859 (1994)		
		CHIO et al., " Identification of a class of sulfonamides highly active against dihydropteroate synthase from <i>Toxoplasma gondii</i> , <i>Pneumocystis carinii</i> , and <i>Mycobacterium avium</i> ," <i>Antimicrobial Agents and Chemotherapy</i> , 40(3):727-733 (1996)		
		CUSHMAN et al., "Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization," <i>Journal of Medicinal Chemistry</i> , 34(8):2579-2588 (1991)		
		HONG et al., "Inhibition of recombinant <i>Pneumocystis carinii</i> dihydropteroate synthetase by sulfa drugs," <i>Antimicrobial Agents and Chemotherapy</i> , 39(8):1756-1763 (1995)		
		LINFIELD et al., "Antibacterially active substituted anilides of carboxylic and sulfonic acids," <i>Journal of Medicinal Chemistry</i> , 26(12):1741-1746 (1983)		
		PATAKOOT et al., "Preparation of some aryls of o, m and p -cresotic acids," <i>Journal of the University of Bombay, Science: Physical Sciences, Mathematics, Biological Sciences and Medicine Section A</i> , 25(40):13-14 (1957)		
		RAMANA et al., "Synthesis of 2-substituted benzoxazoles and benzimidazoles based on mass spectral <i>ortho</i> interactions" <i>Journal of the Chemical Society, Perkin Transactions 2</i> : (7):1497-501 (1995)		
		<b><u>GROUP E</u></b>		
		GRAMMATICAKIS, "No. 165. - Contribution to the study of the absorption in the middle ultraviolet range and the visible range of N-aryl-arylamines. III. - o-, m-, p-methoxybenzoylalkylamines and o-, m-, p- methoxybenzoylarylamines," <i>Bulletin de la Societe Chimique de France</i> , 5:924-935 (1964) (English Language Abstract Attached)		
		WEUFFEN et al., "Investigation of 2-Hydroxythiobenzamides and 2-Hydroxythiobenzanilides. 4th Communication: Preliminary Investigations to		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/671,967
				Filing Date	September 25, 2003; Conf. No. 7271
				First Named Inventor	Jeffrey O. Saunders
				Art Unit	1621
				Examiner Name	Shailendra Kumar
Sheet	<b>5</b>	of	<b>5</b>	Attorney Docket Number	003601-0005-102

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Determine the Anthelmintic Efficacy of the Substances," <i>Pharmazie</i> , 23(6):308-310 (1968) (English Language Summary Attached)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--